CEO of BioSculpture Technology Inc., Robert L. Cucin M.D. speaks about their company’s new technology that addresses Obesity and Type 2 Diabetes.
BioScultpture Technology has a game-changing technology which can do for obesity management and the treatment of Type 2 Diabetes what laser vision correction. We’re currently selling an automatic liposuction device and we have three electronic devices that we will be bringing to market. One, the bariatric treatment market, that’s the EDL device and two for the liposuction market. My earliest patent created the power system liposuction market that grew to be half a billion dollars a year. Three things are unique about the company one is the product itself which allows us to do something that couldn’t be done before. Namely, remove the deep fat inside your abdomen that causes type 2 Diabetes. The second thing is the offering which allows anybody to purchase the stock not just wealthy investors and funds. And the third thing is the fact that the regulatory pathway uses our own device as a predicate. The size of this market is enormous and it’s totally untapped. Our future plans for the company includes opening up branded treatment centers which can cross sell liposuction and also ultra-fat autographed basically, the sky’s the limit to expand the market dramatically.
BioSculpture Technology, Inc. has a game-changing technology which has the potential of doing for Obesity management and the treatment of Type 2 Diabetes mellitus what LASIK did for vision correction.
We have 3 new medical devices that we will be bringing to market:
(1) this revolutionary EVL® device for the bariatric market; and for the liposuction market,
(2) Airbrush Liposculptor IIE, an sleek electrical version of the pneumatic Airbrush® Liposculptor II we’re currently selling; and,
(3) Airbrush® Liposculptor III, a next gen. version of devices manufactured under licenses of my earliest tissue aspiration patent which created the Power Assisted Liposuction (“PAL”) market that grew to be half a billion dollars a year.
Three things are unique about this medical device company.
• The first is the technology and product which allows us to do something that couldn’t be done before, namely, directly remove the deep visceral fat inside your abdomen that causes Type 2 Diabetes.
• The second thing is that the Company’s Offering is a qualified Regulation A which allows anybody to purchase the stock not just wealthy investors and funds.
• And the third thing is the fact that the regulatory pathway uses our own device as a predicate.
The size of this market is enormous and virtually untapped. Given the 10% annual growth of obesity related disease expenditures with $2.1 trillion spent last year, a safer and effective alternative can expand the market dramatically, well beyond the $1.5 billion spent last year for only 208,000 bariatric surgeries, 15% were revisional!
Our future plans for the company includes opening up branded bariatric treatment centers which can also offer liposuction and fat autografting.
For more information on BioSculpture Technology Inc. please fill out the form below.